A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

PHASE3RecruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Atopic Dermatitis

Interventions

DRUG

Jaktinib Hydrochloride Tablet

Orally administered, twice a day

Trial Locations (2)

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjin

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY